Catalyst Pharmaceuticals Inc share price logo

Catalyst Pharmaceuticals Inc

NASDAQ: CPRX

Mid Cap

$28.92

+0.18

(+0.63%)

as on

Catalyst Pharmaceuticals Inc Stock Performance

as on May 5, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $28.45
    $29.30
    downward going graph

    1.63%

    Downside

    1.31%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $19.05
    $32.56
    downward going graph

    34.13%

    Downside

    12.59%

    Upside

    downward going graph

Catalyst Pharmaceuticals Inc share price movements today

Previous Close
$28.74
Open
$28.95
Volume
819.7K
Day's Low - High
$28.45 - $29.30
52 Week Low - High
$19.05 - $32.56

Catalyst Pharmaceuticals Inc Historical Returns

1 Month Return
+ 17.21 %
3 Month Return
+ 21.04 %
1 Year Return
+ 19.09 %
3 Year Return
+ 68.16 %
5 Year Return
+ 526.41 %

Catalyst Pharmaceuticals Inc Stock Fundamentals & Key Indicators

Check Catalyst Pharmaceuticals Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$3.5B

EPS (TTM)

2.8591

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.06%

PE Ratio (TTM)

17.12

Industry PE ratio

-7.903098591549296

PEG Ratio

0

EBITDA

295.7M

Revenue (TTM)

589.0M

Profit Margin

36.39%

Return On Equity TTM

25.49%

Catalyst Pharmaceuticals Inc Stock Valuation

Track how Catalyst Pharmaceuticals Inc P/E has moved over time to understand its valuation trends.

Catalyst Pharmaceuticals Inc in the last 5 years

  • Overview

  • Trends

Lowest (11.37x)

December 31, 2025

Industry (-7.90x)

May 5, 2026

Today (17.12x)

May 5, 2026

Highest (28.83x)

June 30, 2024

LowHigh

Today’s Price to Earnings Ratio: 17.12x

Catalyst Pharmaceuticals Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Catalyst Pharmaceuticals Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$3.5B526.41%17.1236.39%
BUY$39.8B124.56%74.6712.55%
BUY$109.3B100.99%27.732.94%
NA$33.0BNA118.865.37%
BUY$73.5B47.01%17.1229.65%

Stock Returns calculator for Catalyst Pharmaceuticals Inc Stock including INR - Dollar returns

The Catalyst Pharmaceuticals Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Catalyst Pharmaceuticals Inc investment value today

Current value as on today

₹1,34,522

Returns

₹34,522

(+34.52%)

Returns from Catalyst Pharmaceuticals Inc Stock

₹19,012 (+19.01%)

Dollar Impact

₹15,510 (+15.51%)

Analyst Recommendation on Catalyst Pharmaceuticals Inc Stock

Based on 13 analysts

BUY

92.31%

Buy

7.69%

Hold

0.00%

Sell

Based on 13 analysts, 92.31% of analysts recommend a 'BUY' rating for Catalyst Pharmaceuticals Inc. Average target price of $34.14

Catalyst Pharmaceuticals Inc Share Price Target

Get share price movements and forecasts by analysts on Catalyst Pharmaceuticals Inc.

What analysts predicted

15.29%UPSIDE

Target Price

$34.14

Current Price

$28.92

Analyzed by

13 Analysts

Target

$34.14

Catalyst Pharmaceuticals Inc target price $34.14, a slight upside of 15.29% compared to current price of $28.92. According to 13 analysts rating.

Catalyst Pharmaceuticals Inc Stock’s Investor Sentiment and Interest

Search interest for Catalyst Pharmaceuticals Inc Stock has increased by 159% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:159% versus previous 30 day period

Catalyst Pharmaceuticals Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
102
110
98
122
128
141
141
146
148
152
Gross Profit
88
94
85
107
109
120
123
116
123
138
Operating Income
-37
41
27
54
50
62
63
66
66
61
EBITDA
-28
50
36
63
50
72
72
78
80
81
Interest Expense
0
1
-
-
-
-
-
-
-
-
Depreciation
8
9
9
9
9
9
9
9
9
9
Income Before Tax
-38
46
29
55
57
74
71
69
71
71
Income Tax Expense
-7
11
5
14
13
18
14
17
18
19
Net Income
-30
34
23
40
43
55
56
52
52
52
Net Profit Margin
-29.96%
31.51%
23.63%
33.24%
34.10%
39.44%
40.12%
35.55%
35.57%
34.53%

Catalyst Pharmaceuticals Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
0
102
119
140
214
398
491
588
Gross Profit
0
0
0
87
102
118
179
346
422
501
Operating Income
-19
-18
-35
31
41
52
101
86
195
257
EBITDA
-18
-18
-35
32
42
52
103
119
232
321
Interest Expense
0
0
1
1
1
0
4
-
-
-
Depreciation
-
0
0
0
0
0
1
24
37
37
Income Before Tax
-18
-18
-34
33
41
52
104
94
216
283
Income Tax Expense
0
0
2
1
-33
13
21
23
52
69
Net Income
-18
-18
-34
31
74
39
83
71
163
214
Net Profit Margin
0.00%
0.00%
-6800.70%
31.16%
62.97%
28.03%
38.79%
17.93%
33.33%
36.39%

Catalyst Pharmaceuticals Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
34
23
40
43
55
56
52
52
52
Operating Cash Flow
55
31
64
72
70
60
71
32
44
Investing Cash Flow
-38
0
0
0
0
-
0
-
0
Financing Cash Flow
0
141
1
-5
4
3
0
4
-25
Change in Cash
16
172
65
66
75
63
72
37
19

Catalyst Pharmaceuticals Inc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-18
-34
31
74
39
83
71
163
214
Operating Cash Flow
-13
-25
34
45
60
116
143
239
208
Investing Cash Flow
0
-15
37
-5
-11
9
-293
0
0
Financing Cash Flow
57
0
1
0
-8
1
-10
140
-16
Change in Cash
43
-40
72
40
41
126
-160
379
191

Global Institutional Holdings in Catalyst Pharmaceuticals Inc

Funds
Holdings
BlackRock Inc
14.92%
Vanguard Group Inc
6.9%
Qube Research & Technologies
0.83%
The Goldman Sachs Group Inc
0.82%
Arrowstreet Capital Limited Partnership
1.32%

Catalyst Pharmaceuticals Inc News & Key Events

  • img

    Today's Timeline - 25 March

    Wed, 05:53 PM

    -

    Catalyst Pharmaceuticals' 2026 EPS estimates rise from $2.55 to $2.87; Zacks Rank #1 (Strong Buy).

Insights on Catalyst Pharmaceuticals Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, CPRX has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, CPRX has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 4 quarters, 141.42M → 152.61M (in $), with an average increase of 2.5% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, CPRX stock has moved up by 17.2%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 52.78M → 52.69M (in $), with an average decrease of 0.2% per quarter

About Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
OrganisationCatalyst Pharmaceuticals Inc
Headquarters355 Alhambra Circle, Coral Gables, FL, United States, 33134
IndustryBiotechnology
CEOMr. Richard John Daly M.B.A.
E-voting on sharesClick here to vote

Key Management of Catalyst Pharmaceuticals Inc

Name

Title

Dr. Preethi Sundaram Ph.D.

Chief Strategy Officer

Mr. Brian Elsbernd J.D.

Chief Compliance Officer & Chief Legal Officer

Mr. Richard John Daly M.B.A.

President, CEO & Director

Mr. Michael W. Kalb CPA

Executive VP, Treasurer & CFO

Mr. Jeffrey Del Carmen

Executive VP & Chief Commercial Officer

Ms. Mary Coleman

VP & Head of Investor Relations

Dr. William T. Andrews FACP, M.D.

Chief Medical Officer

Mr. Paul Friel

Executive Vice President of Corporate Operations

Mr. Patrick J. McEnany

Co-Founder & Non-Executive Chairman

Dr. Steven R. Miller Ph.D.

Executive VP, COO & Chief Scientific Officer

FAQs

What is Catalyst Pharmaceuticals Inc share price today?

Catalyst Pharmaceuticals Inc share price today is $28.92 as on at the close of the market. Catalyst Pharmaceuticals Inc share today touched a day high of $29.3 and a low of $28.45.

What is the 52 week high and 52 week low for Catalyst Pharmaceuticals Inc share?

Catalyst Pharmaceuticals Inc share touched a 52 week high of $32.56 on and a 52 week low of $19.05 on . Catalyst Pharmaceuticals Inc stock price today i.e. is closed at $28.92,which is 11.18% down from its 52 week high and 51.81% up from its 52 week low.

What is Catalyst Pharmaceuticals Inc's market capitalisation today?

Catalyst Pharmaceuticals Inc market capitalisation is $0.00T as on .

How to invest in Catalyst Pharmaceuticals Inc Stock (CPRX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Catalyst Pharmaceuticals Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Catalyst Pharmaceuticals Inc Shares that will get you 0.0519 shares as per Catalyst Pharmaceuticals Inc share price of $28.92 per share as on May 5, 2026 at 1:29 am IST.

What is the minimum amount required to buy Catalyst Pharmaceuticals Inc Stock (CPRX) from India?

Indian investors can start investing in Catalyst Pharmaceuticals Inc (CPRX) shares with as little as ₹95.28 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹952.80 in Catalyst Pharmaceuticals Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Catalyst Pharmaceuticals Inc share’s latest price of $28.92 as on May 5, 2026 at 1:29 am IST, you will get 0.3458 shares of Catalyst Pharmaceuticals Inc. Learn more about fractional shares .

What are the returns that Catalyst Pharmaceuticals Inc has given to Indian investors in the last 5 years?

Catalyst Pharmaceuticals Inc stock has given 526.41% share price returns and 28.65% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?